在的中青年医师无论写病史还是写论文都喜欢把HER2阳性简写为HER2+。此类简写如果被当年严格的老教授们看到,大多会被责问:这是免疫组化1个“+”还是原位杂交阳性?因为,免疫组化1~2个“+”属于HER2弱阳性,抗HER2药物通常疗效不佳。结果,此类病史或论文通常会被勒令全部重写,要知道当年电脑尚未普及,病史或论文都是用钢笔蘸蓝黑墨水一笔一划写出来的。
-
GeparSepto (NCT01583426): A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer -
GeparOcto (NCT02125344): A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer -
GeparX (NCT02682693): Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design -
GAIN-2 (NCT01690702): Neo-/Adjuvant Phase III Trial to Compare Intense Dose-dense Chemotherapy to Tailored Dose-dense Chemotherapy in Patients With High-risk Early Breast Cancer
-
激素受体阳性率较低:36.7%比64.0%(P<0.0001) -
病理完全缓解率较低:29.2%比39.0%(P=0.0002) -
三年无病生存率较高:83.4%比76.1%(95%置信区间:80.5~85.9、72.9~79.0,分层对数秩检验P=0.0084) -
三年总体生存率较高:91.6%比85.8%(95%置信区间:84.9~93.4、83.0~88.1,分层对数秩检验P=0.0016)
-
病理完全缓解率相似:50.1%比48.0%(P=0.21) -
三年无病生存率较高:84.5%比74.4%(95%置信区间:79.5~88.3、70.2~78.0,分层对数秩检验P=0.0076) -
三年总体生存率较高:90.2%比84.3%(95%置信区间:86.0~93.2、80.7~87.3,分层对数秩检验P=0.016)
-
病理完全缓解率较低:17.5%比23.6%(P=0.024) -
三年无病生存率相似:82.8%比79.3%(95%置信区间:79.1~85.9、73.9~83.7,分层对数秩检验P=0.39) -
三年总体生存率相似:92.3%比88.4%(95%置信区间:89.6~94.4、83.8~91.8,分层对数秩检验P=0.13)
点击文末“阅读全文/Read more”,即可访问《柳叶刀-肿瘤学》官网,阅读研究全文。